NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines
Medicines Update Acute

Amiodarone and hepatitis C anti-virals: avoid concomitant use

A recent MHRA alert advises prescribers of the risks of severe bradycardia and heart block when amiodarone is taken with sofosbuvir/ledipasvir or sofosbuvir/daclatasvir.

Concomitant use of amiodarone and the following anti-viral products, for the management of hepatitis C, should therefore be avoided:

  • Harvoni - a fixed dose combination product of sofosbuvir/ledipasvir
  • Sovaldi (sofosbuvir) in combination with Daklinza (daclatasvir)

These medicines should only be used concomitantly if other anti-arrhythmics are not tolerated or contra-indicated.  Such patients should be closely monitored, particularly during the first week of treatment (see MHRA alert for further advice regarding monitoring).